From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-23-014333 Size: 5 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-23-159011 Act: 34 Size: 49 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001193125-23-158936 Act: 34 Size: 131 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193805-23-000796 Act: 34 Size: 130 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-23-150530 Act: 34 Size: 172 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-23-013455 Size: 9 KB 网页链接
$Cabaletta Bio(CABA)$ 144 Report of proposed sale of securities Accession Number: 0001950047-23-000807 Act: 33 Size: 4 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001193125-23-148212 Act: 34 Size: 510 KB 网页链接
$Cabaletta Bio(CABA)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-23-148191 Act: 33 Size: 634 KB 网页链接
$Cabaletta Bio(CABA)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-23-147294 Act: 33 Size: 640 KB 网页链接